Pfizer (PFE) Earns News Sentiment Rating of 0.14
News headlines about Pfizer (NYSE:PFE) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7981945142779 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s analysis:
- Pfizer, Inc. (NYSE:PFE) Given Buy Rating at Cowen and Company (americanbankingnews.com)
- Pfizer Likely To Remain A Bond Surrogate Until 2020 – Seeking Alpha (seekingalpha.com)
- Analysts Anticipate Pfizer, Inc. (NYSE:PFE) Will Post Earnings of $0.63 Per Share (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Pfizer Inc. (finance.yahoo.com)
- Pfizer, Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
A number of analysts recently weighed in on the stock. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday. Morgan Stanley reaffirmed a “neutral” rating and set a $35.00 target price (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Finally, Citigroup Inc. lowered shares of Pfizer from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average target price of $37.77.
Pfizer (NYSE:PFE) traded up 0.18% during midday trading on Monday, hitting $33.31. 12,791,545 shares of the stock traded hands. Pfizer has a 52-week low of $29.83 and a 52-week high of $35.38. The company has a market cap of $198.79 billion, a price-to-earnings ratio of 24.37 and a beta of 1.00. The firm’s 50-day moving average is $33.40 and its 200-day moving average is $33.31.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. Analysts predict that Pfizer will post $2.56 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In related news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.
WARNING: “Pfizer (PFE) Earns News Sentiment Rating of 0.14” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/pfizer-pfe-earns-news-sentiment-rating-of-0-14/1487912.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.